Lakefront Biotherapeutics NV
GLPGF
$28.08
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.44M | 1.05B | 74.10M | 74.10M | 78.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.44M | 1.05B | 74.10M | 74.10M | 78.90M |
| Cost of Revenue | 41.04M | 125.68M | 113.47M | 113.47M | 206.77M |
| Gross Profit | -33.60M | 922.96M | -39.37M | -39.37M | -127.86M |
| SG&A Expenses | 40.75M | 37.59M | 34.81M | 34.81M | 46.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.24M | -37.39M | -9.46M | -9.46M | -6.94M |
| Total Operating Expenses | 80.54M | 125.88M | 138.82M | 138.82M | 245.92M |
| Operating Income | -73.10M | 922.76M | -64.72M | -64.72M | -167.02M |
| Income Before Tax | 16.02M | 911.67M | -118.51M | -118.51M | -164.55M |
| Income Tax Expenses | 80.30K | 775.30K | 29.50K | 29.50K | -1.91M |
| Earnings from Continuing Operations | 15.94M | 910.89M | -118.54M | -118.54M | -162.64M |
| Earnings from Discontinued Operations | 695.40K | -399.30K | -1.47M | -1.47M | 1.21M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.63M | 910.49M | -120.02M | -120.02M | -161.43M |
| EBIT | -73.10M | 922.76M | -64.72M | -64.72M | -167.02M |
| EBITDA | -63.67M | 932.33M | -44.00M | -44.00M | -158.13M |
| EPS Basic | 0.25 | 13.82 | -1.82 | -1.82 | -2.45 |
| Normalized Basic EPS | 0.15 | 9.23 | -0.83 | -0.83 | -1.56 |
| EPS Diluted | 0.25 | 13.81 | -1.82 | -1.82 | -2.45 |
| Normalized Diluted EPS | 0.15 | 9.22 | -0.83 | -0.83 | -1.56 |
| Average Basic Shares Outstanding | 65.87M | 65.90M | 65.96M | 65.96M | 65.84M |
| Average Diluted Shares Outstanding | 65.87M | 65.92M | 65.96M | 65.96M | 65.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |